Pushing boundaries in biotech
Who are we?
We are a team of data engineers and scientists, driven by the power of cutting-edge AI technology to tackle the most complex biotherapeutic challenges of our time. We’re revolutionizing drug development research, paving the way for better patient outcomes.
BioStrand began as a startup with a mission to revolutionize the way genetic data is analyzed and understood. By integrating biotech, life science, (bio)informatics, and AI, we developed groundbreaking technology that enables large-scale and fully integrated multi-omics analysis. Our goal is to empower researchers and scientists with the tools they need to accelerate drug discovery, improve disease diagnosis, and advance personalized medicine.
In 2022, we were acquired by IPA (ImmunoPrecise Antibodies) who specialize in the research and development of antibodies. This dynamic partnership has allowed us to expand our capabilities and explore new frontiers in biotechnology, creating a powerful synergy between our technologies. With our combined expertise and resources, we are committed to pushing the boundaries of what’s possible in the field of life science and biotechnology.
What we stand for:
Our fundamental drive is to innovate and transform drug discovery, ultimately reducing time while enhancing safety and efficacy. We are proud to be a part of the scientific community and are dedicated to working collaboratively with our partners to create advancements and a better future for all.
Dirk van Hyfte, MD PhD
Head of Innovation
Dirk was appointed Chief Technology Officer when BioStrand was founded in 2019. With a degree in Medicine and specialization as a Psychiatrist from the prestigious University of Leuven in Belgium, Dirk's expertise extends beyond the realms of technology and business.
As a serial entrepreneur, Dirk has already made significant contributions to the field, with several of his groundbreaking ideas earning him patents. Notably, his remarkable achievement, iKnow, caught the attention of IT provider InterSystems, leading to its acquisition in 2010.
In addition to his entrepreneurial ventures, Dirk serves as a Bio-Medical Advisor, seamlessly blending his medical, AI-analytics, technological, and business acumen. He leverages his profound understanding of medical artificial intelligence, having obtained a PhD in the field from Nijmegen University in the Netherlands.
With Dirk at the helm, BioStrand benefits from his diverse skill set and AI-capabilities in healthcare systems, ensuring the company remains at the forefront of innovation in the industry.
Ingrid Brands, MD PhD
Ingrid Brands, a co-founder and former CEO of BioStrand in 2019, now holds the position of General Manager, guiding the company's path towards becoming a global leader in the genetic research domain. With over two decades of experience in senior research and management roles, she has made significant contributions to the field of medicine and neurorehabilitation.
Throughout her career, Dr. Brands has pioneered innovative approaches in neuropsychological rehabilitation, enhancing the care provided to patients with acquired brain injuries. She has held respected research positions at esteemed institutions such as Libra Revalidatie & Audiologie and the Department of Rehabilitation at Erasmus University.
Dr. Brands holds a Ph.D. in neurorehabilitation from the University of Maastricht and graduated with distinction from the University of Leuven, specializing in Physical Medicine and Rehabilitation (PM&R). Her commitment to advancing the field is evident in her academic achievements and active involvement in professional committees.
Under Dr. Brands' leadership, BioStrand continues to evolve, utilizing cutting-edge research and technology to drive advancements in genetic research. Her dedication to innovation and patient care serves as the driving force behind BioStrand's achievements.
Arnout van Hyfte
Head of Products & Platform
Arnout's journey with BioStrand began in 2019, as a key member of the founding team. Embracing the role of Chief Commercial Officer, he has played a pivotal role in shaping the company's commercial strategies, setting the stage for its remarkable growth.
With a keen eye for detail and an unwavering commitment to excellence, Arnout has built a robust infrastructure that forms the very foundation of BioStrand's operations. This strategic groundwork has propelled the company to achieve unprecedented global scale-up over the past five years.
In addition to his overarching responsibilities, Arnout deftly oversees the development team, ensuring their seamless coordination and fostering a culture of innovation. His leadership extends to crafting effective sales and marketing strategies, as well as engaging with the market to cultivate meaningful relationships.
Through Arnout's unwavering dedication and astute management, BioStrand continues to thrive, positioning itself as a trailblazer in its industry.
Carlo Wouters, PhD
Head of Technology
Carlo joined BioStrand as Head of Technology in 2022, leveraging his prior experience as a consultant and entrepreneur. With a focus on managing teams for complex data-driven integration architectures, he brings a wealth of expertise in Enterprise Architecture, Information and Data Management, Integration Architectures, and Software Development.
Carlo's consultancy career spans decades, assisting companies in auditing and creating high-quality solution architectures while leading implementation teams. He is passionate about nurturing talent through training, coaching, and mentoring. His entrepreneurial mindset drives his interest in company strategies, management, and value creation.
Carlo holds a Master's degree in Information Technology and a Ph.D. in Computer Science (Automated Sub-Ontology Extraction) from La Trobe University, Melbourne, Australia.
As BioStrand's Head of Technology, Carlo plays a crucial role in driving the company's success by harnessing cutting-edge technologies and innovative solutions.
Team approach - the power of partnership:
We’re a technology company that works collaboratively with your team to develop a tailored solution that fits your unique needs. Our approach is centered on seamless integration, shared knowledge and partnership. Together, we’ll leverage the latest data and insight with LENSai™ to optimize your operations and drive growth.
The internal analytics
50% Of employees hold PhDs
41% Diversity: employees from different cultures
In silico, in vitro and in vivo drug discovery - a powerful combination
Two companies with one mission. Accelerate biotherapeutic research, technology and drug discovery that maximizes efficiencies while improving safety and efficacy, ultimately paving the way for a brighter future and better patient outcomes.
IPA (ImmunoPrecise Antibodies) Parent Company
IPA is a global parent company with multiple independently operating subsidiaries, including BioStrand, with a common goal of being the HUB of Biotherapeutic Intelligence. At the forefront of the field, the primary focus is on accelerating critical research methods that bring novel therapeutics to reality. As a contract research organization and protein manufacturer, IPA leverages its expertise to provide specialized services to accelerate antibody drug discovery and development. #1 globally ranked CRO1.
BioStrand is a rapidly growing global AI company fueled by creating change and the pursuit of better outcomes. The innovative minds behind the patented HYFT® technology have revolutionized the way we understand the biosphere, developing it into the powerful LENSai platform. This transformative platform provides unparalleled insights into the intricate connections that exist within the biotherapeutic environment, unlocking a deeper understanding of the world around us. Through LENSai, we gain new perspectives and make meaningful strides towards solving the greatest challenges. BioStrand provides customized and scaleable data management solutions and antibody discovery.